ALB and chronic kidney disease: Despite treatment with current standard of care, patients with CKD and T2D havehigh residual cardiorenal morbidity and mortality.6,60,67, -69 Efforts have been made toassess risk based on an individual’s eGFR and albumin-to-creatinine ratio (eg,the heat map included in the KDIGO CKD guidelines).70 Hemodynamic factors,metabolic factors, and inflammation and fibrosis are key drivers of CKDprogression in T2D.